Khin Yadanar Phyo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Khin Yadanar Phyo has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Bo Bo Lay
School of Information Technology, Mae Fah Luang University, Chiang Rai 57100, Thailand
4 shared publications - Myat Mon San
Biomedical Technology Research Group for Vulnerable Populations and School of Health Science, Mae Fah Luang University, Chiang Rai 57100, Thailand
4 shared publications - Rinrada Pattanayaiying
Department of Food innovation and Professional chef, Faculty of Science and Technology, Suan Sunandha Rajabhat University, Bangkok 10300, Thailand
4 shared publications - Sasitorn Chusri
Affiliation Biomedical Technology Research Group for Vulnerable Populations and School of Health Science, Mae Fah Luang University, Muang, Chiang Rai, Thailand
4 shared publications - Wai Phyo Lin
Biomedical Technology Research Group for Vulnerable Populations and School of Health Science, Mae Fah Luang University, Chiang Rai 57100, Thailand
4 shared publications - Samuel Abiodun Kehinde
Biomedical Technology Research Group for Vulnerable Populations and School of Health Science, Mae Fah Luang University, Chiang Rai 57100, Thailand
3 shared publications
Latest Publications
- Open Access
Clinical Potential of Curcuma longa Linn. as Nutraceutical/Dietary Supplement for Metabolic Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Metabolic syndrome (MetS) and its associated conditions, namely, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), obesity, and polycystic ovary syndrome (PCOS) are characterized by insulin resistance, dyslipidemia, and low-grade inflammation. Curcumin, a polyphenolic compound derived from Curcuma longa Linn., exhibits pleiotropic metabolic and anti-inflammatory properties and has thus been evaluated as a nutraceutical intervention for these conditions, but findings remain inconsistent. This systematic review and meta-analysis evaluated the clinical efficacy of Curcuma longa supplementation on anthropometric, glycemic, lipid, inflammatory, and oxidative stress parameters in adults with MetS or related disorders. A comprehensive search of databases (PubMed, Scopus, AMED, LILACS, and Google Scholar) identified 104 eligible randomized controlled trials (RCTs). The included trials primarily assessed standardized oral turmeric/curcumin supplements and bioavailability-enhanced formulations rather than whole culinary turmeric. Pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs) were computed using random-effects models. Subgroup analyses were conducted by disease category, dose, and formulation. Risk of bias was assessed using the Cochrane RoB 2 tool. Curcumin supplementation significantly reduced fasting blood sugar (SMD = −0.54, 95% CI −0.72 to −0.36) and HbA1c (SMD = −0.41, 95% CI −0.60 to −0.23) in T2DM; decreased triglycerides (SMD = −0.48; 95% CI: −0.70 to −0.25), and LDL cholesterol (SMD = −0.39; 95% CI: −0.59 to −0.18) while elevating HDL cholesterol (SMD = 0.45; 95% CI: 0.25 to 0.65) and total antioxidant capacity (SMD = 0.73; 95% CI: 0.51 to 0.94). Curcuma longa also attenuated systemic inflammation, lowering C-reactive protein (SMD = −0.62; 95% CI: −0.81 to −0.43), TNF-α (SMD = −0.57; 95% CI: −0.80 to −0.34), and IL-6 (SMD = −0.50; 95% CI: −0.70 to −0.29). Heterogeneity was moderate-to-high, reflecting some differences in the formulation, dosage, and duration. Collectively, these findings affirm that Curcuma longa exerts measurable, clinically relevant improvements on glycemic regulation, lipid metabolism, and inflammatory−oxidative balance, supporting its role as a nutraceutical adjunct in metabolic health management, while its bioavailability-enhanced formulations show superior efficacy. Larger, long-term, multicenter RCTs are warranted to confirm durability, optimal dosing, and safety.
Open AccessClinical Potential of Curcuma longa Linn. as Nutraceutical/Dietary Supplement for Metabolic Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Metabolic syndrome (MetS) and its associated conditions, namely, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), obesity, and polycystic ovary syndrome (PCOS) are characterized by insulin resistance, dyslipidemia, and low-grade inflammation. Curcumin, a polyphenolic compound derived from Curcuma longa Linn., exhibits pleiotropic metabolic and anti-inflammatory properties and has thus been evaluated as a nutraceutical intervention for these conditions, but findings remain inconsistent. This systematic review and meta-analysis evaluated the clinical efficacy of Curcuma longa supplementation on anthropometric, glycemic, lipid, inflammatory, and oxidative stress parameters in adults with MetS or related disorders. A comprehensive search of databases (PubMed, Scopus, AMED, LILACS, and Google Scholar) identified 104 eligible randomized controlled trials (RCTs). The included trials primarily assessed standardized oral turmeric/curcumin supplements and bioavailability-enhanced formulations rather than whole culinary turmeric. Pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs) were computed using random-effects models. Subgroup analyses were conducted by disease category, dose, and formulation. Risk of bias was assessed using the Cochrane RoB 2 tool. Curcumin supplementation significantly reduced fasting blood sugar (SMD = −0.54, 95% CI −0.72 to −0.36) and HbA1c (SMD = −0.41, 95% CI −0.60 to −0.23) in T2DM; decreased triglycerides (SMD = −0.48; 95% CI: −0.70 to −0.25), and LDL cholesterol (SMD = −0.39; 95% CI: −0.59 to −0.18) while elevating HDL cholesterol (SMD = 0.45; 95% CI: 0.25 to 0.65) and total antioxidant capacity (SMD = 0.73; 95% CI: 0.51 to 0.94). Curcuma longa also attenuated systemic inflammation, lowering C-reactive protein (SMD = −0.62; 95% CI: −0.81 to −0.43), TNF-α (SMD = −0.57; 95% CI: −0.80 to −0.34), and IL-6 (SMD = −0.50; 95% CI: −0.70 to −0.29). Heterogeneity was moderate-to-high, reflecting some differences in the formulation, dosage, and duration. Collectively, these findings affirm that Curcuma longa exerts measurable, clinically relevant improvements on glycemic regulation, lipid metabolism, and inflammatory−oxidative balance, supporting its role as a nutraceutical adjunct in metabolic health management, while its bioavailability-enhanced formulations show superior efficacy. Larger, long-term, multicenter RCTs are warranted to confirm durability, optimal dosing, and safety.
- Open Access
- 5 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1911
Preclinical Evidence of Curcuma longa Linn. as a Functional Food in the Management of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Rodent Studies
Background/Objectives: Metabolic syndrome (MetS) is a multifactorial condition characterized by abdominal obesity, dyslipidemia, insulin resistance, hypertension, and chronic inflammation. As its global prevalence rises, there is increasing interest in natural, multi-targeted approaches to manage MetS. Curcuma longa Linn. (turmeric), especially its active compound curcumin, has shown therapeutic promise in preclinical studies. This systematic review and meta-analysis evaluated the effects of Curcuma longa and its derivatives on MetS-related outcomes in rodent models. Methods: A comprehensive search was conducted across six databases (PubMed, Scopus, AMED, LILACS, MDPI, and Google Scholar), yielding 47 eligible in vivo studies. Data were extracted on key metabolic, inflammatory, and oxidative stress markers and analyzed using random-effects models. Results were presented as mean differences (MD) with 95% confidence intervals (CI). Results: Meta-analysis showed that curcumin significantly reduced body weight (rats: MD = −42.10; mice: MD = −2.91), blood glucose (rats: MD = −55.59; mice: MD = −28.69), triglycerides (rats: MD = −70.17; mice: MD = −24.57), total cholesterol (rats: MD = −35.77; mice: MD = −52.61), and LDL cholesterol (rats: MD = −69.34; mice: MD = −42.93). HDL cholesterol increased significantly in rats but not in mice. Inflammatory cytokines were markedly reduced, while oxidative stress improved via decreased malondialdehyde (MDA) and elevated superoxide dismutase (SOD) and catalase (CAT) levels. Heterogeneity was moderate to high, primarily due to variations in curcumin dosage (ranging from 10 to 500 mg/kg) and treatment duration (2 to 16 weeks) across studies. Conclusions: This preclinical evidence supports Curcuma longa as a promising functional food component for preventing and managing MetS. Its multi-faceted effects warrant further clinical studies to validate its translational potential.
- 5 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1911
Open AccessPreclinical Evidence of Curcuma longa Linn. as a Functional Food in the Management of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Rodent Studies
Background/Objectives: Metabolic syndrome (MetS) is a multifactorial condition characterized by abdominal obesity, dyslipidemia, insulin resistance, hypertension, and chronic inflammation. As its global prevalence rises, there is increasing interest in natural, multi-targeted approaches to manage MetS. Curcuma longa Linn. (turmeric), especially its active compound curcumin, has shown therapeutic promise in preclinical studies. This systematic review and meta-analysis evaluated the effects of Curcuma longa and its derivatives on MetS-related outcomes in rodent models. Methods: A comprehensive search was conducted across six databases (PubMed, Scopus, AMED, LILACS, MDPI, and Google Scholar), yielding 47 eligible in vivo studies. Data were extracted on key metabolic, inflammatory, and oxidative stress markers and analyzed using random-effects models. Results were presented as mean differences (MD) with 95% confidence intervals (CI). Results: Meta-analysis showed that curcumin significantly reduced body weight (rats: MD = −42.10; mice: MD = −2.91), blood glucose (rats: MD = −55.59; mice: MD = −28.69), triglycerides (rats: MD = −70.17; mice: MD = −24.57), total cholesterol (rats: MD = −35.77; mice: MD = −52.61), and LDL cholesterol (rats: MD = −69.34; mice: MD = −42.93). HDL cholesterol increased significantly in rats but not in mice. Inflammatory cytokines were markedly reduced, while oxidative stress improved via decreased malondialdehyde (MDA) and elevated superoxide dismutase (SOD) and catalase (CAT) levels. Heterogeneity was moderate to high, primarily due to variations in curcumin dosage (ranging from 10 to 500 mg/kg) and treatment duration (2 to 16 weeks) across studies. Conclusions: This preclinical evidence supports Curcuma longa as a promising functional food component for preventing and managing MetS. Its multi-faceted effects warrant further clinical studies to validate its translational potential.
- Open Access
- 21 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 7026
Curcumin and Dementia: A Systematic Review of Its Effects on Oxidative Stress and Cognitive Outcomes in Animal Models
Dementia is marked by progressive cognitive decline linked to oxidative stress, neuroinflammation, and synaptic dysfunction. Curcumin, a natural compound from Curcuma longa, has shown promising neuroprotective effects. This systematic review analyzed 29 preclinical studies using rodent models of dementia induced by chemical, genetic, or dietary methods. The review focused on curcumin’s effects on oxidative stress, inflammation, and cognitive outcomes. All studies assessing malondialdehyde (MDA) reported significant reductions, indicating reduced oxidative stress. Superoxide dismutase (SOD) activity increased in all measured cases, while glutathione (GSH) levels rose in about one-third of studies. A literature search was comprehensively conducted using PubMed, Scopus, AMED, and LILACS databases through April 2024. Curcumin also demonstrated anti-inflammatory properties, with over 80% of studies showing reduced levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. Additionally, 40% of studies noted increases in anti-inflammatory markers like IL-4 and IGF-1. Cognitive performance improved in around 80% of studies, especially in spatial learning and memory. Some studies also reported behavioral improvements, including reduced anxiety and enhanced locomotion. Curcumin demonstrated potent antioxidative, anti-inflammatory, and cognitive-enhancing effects across diverse dementia models. Its ability to modulate multiple pathological pathways highlights its potential as a bioactive compound for mitigating cognitive decline associated with neurodegenerative diseases. However, variability in study design and curcumin formulations suggests the need for standardized protocols and further high-quality research to facilitate clinical translation.
- 21 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 7026
Open AccessCurcumin and Dementia: A Systematic Review of Its Effects on Oxidative Stress and Cognitive Outcomes in Animal Models
Dementia is marked by progressive cognitive decline linked to oxidative stress, neuroinflammation, and synaptic dysfunction. Curcumin, a natural compound from Curcuma longa, has shown promising neuroprotective effects. This systematic review analyzed 29 preclinical studies using rodent models of dementia induced by chemical, genetic, or dietary methods. The review focused on curcumin’s effects on oxidative stress, inflammation, and cognitive outcomes. All studies assessing malondialdehyde (MDA) reported significant reductions, indicating reduced oxidative stress. Superoxide dismutase (SOD) activity increased in all measured cases, while glutathione (GSH) levels rose in about one-third of studies. A literature search was comprehensively conducted using PubMed, Scopus, AMED, and LILACS databases through April 2024. Curcumin also demonstrated anti-inflammatory properties, with over 80% of studies showing reduced levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. Additionally, 40% of studies noted increases in anti-inflammatory markers like IL-4 and IGF-1. Cognitive performance improved in around 80% of studies, especially in spatial learning and memory. Some studies also reported behavioral improvements, including reduced anxiety and enhanced locomotion. Curcumin demonstrated potent antioxidative, anti-inflammatory, and cognitive-enhancing effects across diverse dementia models. Its ability to modulate multiple pathological pathways highlights its potential as a bioactive compound for mitigating cognitive decline associated with neurodegenerative diseases. However, variability in study design and curcumin formulations suggests the need for standardized protocols and further high-quality research to facilitate clinical translation.
- Open Access
The Impact of Kefir Consumption on Inflammation, Oxidative Stress Status, and Metabolic-Syndrome-Related Parameters in Animal Models: A Systematic Review and Meta-Analysis
Metabolic syndrome (MetS) is a complex condition defined by central obesity, insulin resistance, dyslipidemia, and systemic inflammation. Kefir, a fermented beverage rich in probiotics and beneficial compounds, has emerged as a functional food that may offer metabolic advantages. Nevertheless, preclinical results have been variable. This systematic review and meta-analysis aimed to assess the influence of kefir and its derived compositions on parameters associated with MetS, inflammation, and oxidative stress in rodent studies. A comprehensive literature search was conducted in PubMed, Scopus, AMED, and LILACS through June 2024. Eligible studies involving kefir interventions in rodent MetS models were included. Data extraction followed PRISMA guidelines, with the risk of bias assessed using the CAMARADES and SYRCLE tools. Meta-analyses were performed with a random effects model. Thirty-eight studies involving 1462 rodents (mice and rats) were analyzed. Kefir significantly reduced body weight gain in both mice (MD = –3.33; 95% CI: –4.89 to –1.77) and rats (MD = –41.53; 95% CI: –54.33 to –28.72). In mice, triglycerides and LDL-C levels decreased significantly; in rats, kefir lowered total cholesterol and triglycerides. Insulin levels were reduced (MD = –0.69; 95% CI: –1.16 to –0.22), suggesting improved insulin sensitivity. Several studies also reported reductions in TNF-α, IL-1β, and IL-6. Despite promising results, the high heterogeneity and methodological variability emphasize the need for standardized preclinical protocols and clinical validation. These findings support the role of kefir as a functional food for metabolic health promotion.
Open AccessThe Impact of Kefir Consumption on Inflammation, Oxidative Stress Status, and Metabolic-Syndrome-Related Parameters in Animal Models: A Systematic Review and Meta-Analysis
Metabolic syndrome (MetS) is a complex condition defined by central obesity, insulin resistance, dyslipidemia, and systemic inflammation. Kefir, a fermented beverage rich in probiotics and beneficial compounds, has emerged as a functional food that may offer metabolic advantages. Nevertheless, preclinical results have been variable. This systematic review and meta-analysis aimed to assess the influence of kefir and its derived compositions on parameters associated with MetS, inflammation, and oxidative stress in rodent studies. A comprehensive literature search was conducted in PubMed, Scopus, AMED, and LILACS through June 2024. Eligible studies involving kefir interventions in rodent MetS models were included. Data extraction followed PRISMA guidelines, with the risk of bias assessed using the CAMARADES and SYRCLE tools. Meta-analyses were performed with a random effects model. Thirty-eight studies involving 1462 rodents (mice and rats) were analyzed. Kefir significantly reduced body weight gain in both mice (MD = –3.33; 95% CI: –4.89 to –1.77) and rats (MD = –41.53; 95% CI: –54.33 to –28.72). In mice, triglycerides and LDL-C levels decreased significantly; in rats, kefir lowered total cholesterol and triglycerides. Insulin levels were reduced (MD = –0.69; 95% CI: –1.16 to –0.22), suggesting improved insulin sensitivity. Several studies also reported reductions in TNF-α, IL-1β, and IL-6. Despite promising results, the high heterogeneity and methodological variability emphasize the need for standardized preclinical protocols and clinical validation. These findings support the role of kefir as a functional food for metabolic health promotion.